

Appl. No. 09/913,788
Amdt. dated March 10, 2004
Reply to Office Action of 01/28/04

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please cancel claims 9-21

Claim 22 (currently amended) A compound comprising:

(a) a biomolecule selected from somatostatin, neurotensin, bombesin-receptor binding molecules, antibodies, ~~penetratines~~TM PenetratinTM peptides, and molecules binding to GPIIb/GPIIIa receptors;

coupled to

(b) an aromatic intercalating moiety with binding affinity for double-stranded DNA selected from acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole, and tetracycline compounds with cytostatic activity;

which is complexed to

(c) a γ -emitting radioactive metal selected from Tc-99m, Re-186, Re-188, and Mn,

wherein said compound is associated with one or more pharmaceutically acceptable excipients.

Please cancel claims 23-24

Claim 25 (currently amended) A kit for the preparation of a diagnostic or therapeutic

Appl. No. 09/913,788
Amdt. dated March 10, 2004
Reply to Office Action of 01/28/04

composition comprising:

- (a) a biomolecule molecule selected from somatostatin, neurotensin, bombesin-receptor binding molecules, antibodies, ~~penetratines~~[™] Penetratin[™] peptides, and molecules binding to GPIIb/IIIa receptors;
coupled to
- (b) an aromatic intercalating moiety with binding affinity for double-stranded DNA selected from acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole, and tetracycline compounds with cytostatic activity;
- (c) instructions to combine the above composition with a γ -emitting radioactive metal selected from Tc-99m, Re-186, Re-188, and Mn; and
- (d) one or more pharmaceutically acceptable excipients.